Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT

Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination and antibodies from patients with spontaneous heparin-induced thrombocytopenia (HIT) and classical HIT. VITT antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanack, Adam J., Bayas, Antonios, George, Gemlyn, Abou-Ismail, Mouhamed Yazan, Singh, Bandana, Kohlhagen, Mindy C., Splinter, Noah P., Christ, Monika, Naumann, Markus, Moser, Karen A., Smock, Kristi J., Grazioli, Alison, Wen, Renren, Wang, Demin, Murray, David L., Padmanabhan, Anand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Letter to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262283/
https://www.ncbi.nlm.nih.gov/pubmed/35560046
http://dx.doi.org/10.1182/blood.2021014588
Descripción
Sumario:Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination and antibodies from patients with spontaneous heparin-induced thrombocytopenia (HIT) and classical HIT. VITT antibodies are monoclonal or oligoclonal, similar to spontaneous HIT, whereas classical HIT antibodies are polyclonal. Heparin inhibits antibody-induced platelet activation in VITT, suggesting that heparin should be considered for the treatment of VITT.

Ejemplares similares